指南与共识冠心病血脂与心血管预防

2019 ESC/EAS血脂指南在近期心梗患者全国数据中的模拟应用

Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
指南 / 共识 · Eur Heart J · 2020-01-01

基于瑞典SWEDEHEART登记中25 466例近期心梗患者,模拟2019 ESC/EAS血脂指南下强化降脂的达标情况。82.9%患者未达LDL-C<1.4 mmol且降幅≥50%的目标,最大化他汀联合依折麦布后约半数仍需PCSK9抑制剂,约90%可达标。

要点

  • 近期心梗患者中82.9%未达2019 ESC/EAS的LDL-C目标。
  • 强化他汀联合依折麦布后50.7%仍符合PCSK9抑制剂指征。
  • 模拟使用PCSK9抑制剂后约90%患者可达LDL-C目标。

核心结论

  • 即使最大化高强度他汀和依折麦布,约半数心梗患者仍符合PCSK9抑制剂治疗指征。
  • 新指南下PCSK9抑制剂的经济负担可能较大。

研究设计与样本

  • 基于瑞典SWEDEHEART全国登记,纳入25 466例心梗后6-10周随访患者(2013-17年)。
  • 采用蒙特卡洛模型模拟强化降脂治疗对LDL-C达标的影响。

主要发现

  • 86.6%患者使用高强度他汀,82.9%未达LDL-C<1.4 mmol且降幅≥50%的目标。
  • 模拟高强度他汀单药使19.9%达标,联合依折麦布另使28.5%达标。
  • 50.7%患者仍符合PCSK9抑制剂指征,模拟使用后约90%总患者达标。

关键数值与推荐

  • LDL-C目标为<1.4 mmol且较基线降低≥50%。

临床怎么用

  • 对近期心梗患者应评估LDL-C是否达到<1.4 mmol且降幅≥50%。
  • 未达标者依次考虑高强度他汀、依折麦布及PCSK9抑制剂。

局限性

  • 为模拟研究,非真实治疗干预结果。
  • 基于瑞典登记数据,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To estimate the proportion of patients with a recent myocardial infarction (MI) who would be eligible for additional lipid-lowering therapy according to the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for the management of dyslipidaemias, and to simulate the effects of expanded lipid-lowering therapy on attainment of the low-density lipoprotein cholesterol (LDL-C) target as recommended by the guidelines. METHODS AND RESULTS: Using the nationwide SWEDEHEART register, we included 25 466 patients who had attended a follow-up visit 6-10 weeks after an MI event, 2013-17. While most patients (86.6%) were receiving high-intensity statins, 82.9% of the patients would be eligible for expanded lipid-lowering therapy, as they had not attained the target of an LDL-C level of <1.4 mmol and a ≥50% LDL-C level reduction. When maximized use of high-intensity statins followed by add-on therapy with ezetimibe was simulated using a Monte Carlo model, the LDL-C target was reached in 19.9% using high-intensity statin monotherapy and in another 28.5% with high-intensity statins and ezetimibe, while 50.7% would still be eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. When use of alirocumab or evolocumab was simulated in those who were eligible for PCSK9 inhibitors, around 90% of all patients attained the LDL-C target. CONCLUSION: Our study suggests that, even with maximized use of high-intensity statins and ezetimibe, around half of patients with MI would be eligible for treatment with PCSK9 inhibitors according to the 2019 ESC/EAS guidelines. Considering the current cost of PCSK9 inhibitors, the financial implications of the new guidelines may be substantial.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Allahyari A, Jernberg T, Hagström E, et al. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020. PMID: 32072178. doi:10.1093/eurheartj/ehaa034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。